• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Paragonix has positive long-term data on heart preservation

Paragonix has positive long-term data on heart preservation

April 12, 2024 By Sean Whooley

Paragonix SherpaPak donor heart preservation system
The SherpaPak donor heart preservation system. [Image courtesy of Paragonix]
Paragonix Technologies today announced positive long-term registry results demonstrating improvements after heart transplantation.

Results from the GUARDIAN-Heart registry demonstrated statistically significant improvements in 2-year survival following heart transplantation. The analysis consisted of a total of 1,261 U.S. adult patients matched using statistical propensity matching. This created two cohorts of equal baseline characteristics to compare the SherpaPak system against traditional ice storage.

SherpaPak offers static hypothermic preservation for hearts during transportation and eventual transplantation. It utilizes cold storage solutions indicated for use with the heart.

Looking at the results from the Paragonix registry

The matched cohorts in this registry featured 362 patients each. Paragonix said its SherpaPak heart preservation system led to a 5% increase in two-year survival. That represents a 43% reduction in two-year mortality. Additionally, the study saw a 50% reduction in severe primary graft dysfunction within 24 hours post-trasplant.

Paragonix said it observed a 32% reduction in all post-transplant mechanical circulatory support (MCS). That includes MCS continued from pre-transplant throughout the post-transplant period. SherpaPak led to a 39% reduction in new extracorporeal membrane oxygenation (ECMO)/ventricular asisst device (VAD) post-transplant. Finally, the study recorded a 44% reduction in severe right ventricular dysfunction (RVD) with SherpaPak.

Dr. Scott Silvestry served as lead investigator for the study. Silvestry said the results highlight the possibility of saving 1-5 lives per year thanks to the survival difference with SherpaPak.

“For as long as heart transplant has been a discipline, we have been racing against the clock,” said Dr. David D’Alessandro, a lead investigator and surgical director of heart transplantation and ventricular assist devices at Massachusetts General Hospital. “This study indicates that the SherpaPak System can attenuate the risks of ischemic time through controlled hypothermic and isobaric preservation. Our findings showed that hearts performed better in a SherpaPak than on ice across all examined ischemic timeframes – whether it’s simply one hour or very long-distance procurements.”

Filed Under: Cardiovascular, Clinical Trials, Featured, Transplants Tagged With: Paragonix Technologies

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy